Gene Fusions in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 17
Special Issue Editors
Interests: cancer genomics; sarcoma; targeted therapies; cancer evolution; drug resistance mechanisms
Special Issue Information
Dear Colleagues,
The importance of gene fusions in cancer has been recognised since 1984 when the chronic myeloid leukaemia-associated Philadelphia chromosome was found to result in the fusion of the BCR and ABL1 genes. Since then, oncogenic gene fusions have been shown to be widespread in both haematological malignancies and solid tumours. Their clinical importance may be profound with gene fusions, such as those involving ABL1, ALK or NTRK, representing some of the most successful examples of targeted therapy. Furthermore, many cancers, particularly certain sarcomas and leukaemias, are defined by the presence of a specific oncogenic fusion and they are, thus, diagnostically critical. The advent of whole genome and RNA-based next-generation sequencing technologies over the past decade has resulted in the characterisation of a plethora of novel oncogenic fusions, the molecular pathogeneses and clinical impacts of which largely remain obscure.
This Special Issue will explore recent developments in both the mechanistic and clinical aspects of oncogenic gene fusions.
Dr. Christopher R. McEvoy
Dr. Ing Soo Tiong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene fusions
- targeted therapy
- cancer diagnostics
- molecular pathology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
